Trump Sets Pharma Tariffs Deadline. The Fallout for Lilly, Pfizer, Other Drugmakers
AstraZeneca Hits 4-week High
AstraZeneca (AZN.US) BTK inhibitor new indication approved by the EU for the treatment of mantle cell lymphoma.
AstraZeneca (AZN.US) announced that acalabrutinib in combination with bendamustine and rituximab has been approved in the European Union for the treatment of adult patients with mantle cell lymphoma (MCL) who have not received prior treatment and are not suitable for autologous stem cell transplantation.
AstraZeneca's Calquence Regimen Wins EU Approval for Mantle Cell Lymphoma
AstraZeneca's (LON:AZN) Earnings Offer More Than Meets The Eye
India Offers US Reciprocal Zero Tariffs on Steel, Auto Parts, Pharmaceutical Drugs, Bloomberg Reports
AstraZeneca First Quarter 2025 Earnings: EPS Beats Expectations, Revenues Lag
AstraZeneca Announces KALOS, LOGOS Trials Met All Primary Endpoints
AstraZeneca's Fixed-Dose Triple-Combination Therapy BREZTRI AEROSPHERE Meets Primary Endpoints In KALOS And LOGOS Phase III Trials In Asthma
AstraZeneca Reported High-level Results From The Phase 3 KALOS and LOGOS Trials, Showing Fixed-dose Triple-combination Therapy Breztri Aerosphere Met All Primary Endpoints In Patients With Uncontrolled Asthma
AstraZeneca's Asthma Drug Improves Lung Function in Late-stage Studies
AstraZeneca Director Invests in Company Shares
European Equities Traded in the US as American Depositary Receipts Track Lower in Thursday Trading
New Cancer Treatments Spark Hope as Traditional Funding Faces Uncertainty
AstraZeneca Announces Current Voting Rights and Share Capital Structure
FDA to Tighten Vaccine Approval Requirements: Reports
Trump Administration Said to Be Investing $500M on Developing Universal Vaccines
Goldman Sachs Keeps Their Buy Rating on AstraZeneca (AZN)
AstraZeneca Price Target Lowered to 13,700 GBp at Morgan Stanley
Research Alert: CFRA Keeps Strong Buy Opinion On Adss Of Astrazeneca Plc